Capivasertib联合恩杂鲁胺治疗mCRPC的I期剂量递增研究
这项I期剂量递增研究评估了AKT抑制剂capivasertib联合恩杂鲁胺在既往接受过阿比特龙和/或恩杂鲁胺治疗失败的转移性去势抵抗性前列腺癌(mCRPC)患者中的安全性、耐受性和初步抗肿瘤活性。推荐的II期剂量为capivasertib 400 mg每日两次(用4天停3天),联合恩杂鲁胺160 mg每日一次,最常见≥3级不良事件为高血糖(26.7%)和皮疹(20%)。联合方案耐受性可,并显示出抗肿瘤活性,所有应答患者均携带PI3K/AKT/mTOR通路异常。
要点
- 推荐II期剂量:capivasertib 400 mg每日两次(用4天停3天)联合恩杂鲁胺160 mg每日一次。
- 常见≥3级不良事件为高血糖(26.7%)和皮疹(20%),该剂量下DLT为斑丘疹(1/6)。
- 恩杂鲁胺显著降低capivasertib血浆暴露,但似未影响药效学。
核心结论
- Capivasertib联合恩杂鲁胺在既往治疗失败的mCRPC患者中耐受性可,并具有抗肿瘤活性,所有应答患者均携带PI3K/AKT/mTOR通路异常。
研究设计与样本
- I期剂量递增研究,纳入既往阿比特龙和/或恩杂鲁胺治疗失败的mCRPC患者,capivasertib起始320 mg每日两次(用4天停3天)联合恩杂鲁胺160 mg每日一次。
- 共16例患者入组,15例接受研究治疗,13例可评估剂量限制性毒性(DLT)。
- 共同主要终点为安全性和耐受性、确定最大耐受剂量和推荐II期剂量,同时评估药代动力学、抗肿瘤活性和探索性生物标志物。
主要发现
- 患者在capivasertib 320、400和480 mg每日两次剂量水平接受治疗,推荐II期剂量为400 mg每日两次,该水平1/6例患者发生DLT(斑丘疹)。
- 最常见≥3级不良事件为高血糖(26.7%)和皮疹(20%)。
- 恩杂鲁胺合用显著降低capivasertib血浆暴露,但似未影响药效学。
- 3例患者达到应答标准(定义为前列腺特异性抗原下降≥50%、循环肿瘤细胞转换和/或影像学应答)。
- 应答见于PTEN缺失或AKT激活突变、AR-V7低表达或不表达、以及暴露后样本中磷酸化细胞外信号调节激酶(pERK)升高的患者。
关键数值与推荐
- 推荐II期剂量:capivasertib 400 mg每日两次(用4天停3天)联合恩杂鲁胺160 mg每日一次。
- DLT定义及应答标准(前列腺特异性抗原下降≥50%、循环肿瘤细胞转换和/或影像学应答)按原文报告。
- 常见≥3级不良事件发生率:高血糖26.7%,皮疹20%。
临床怎么用
- 对于既往阿比特龙和/或恩杂鲁胺治疗失败的mCRPC患者,可考虑capivasertib 400 mg每日两次(用4天停3天)联合恩杂鲁胺160 mg每日一次,但需监测高血糖和皮疹。
- 恩杂鲁胺合用降低capivasertib暴露,临床联合用药时需关注药代动力学相互作用。
- 应答患者均携带PI3K/AKT/mTOR通路异常,提示该通路改变可能作为生物标志物指导患者选择。
局限性
- 样本量小(16例入组,13例可评估DLT),结果需更大样本验证。
- 为I期剂量递增研究,抗肿瘤活性为初步探索性结果。
- 恩杂鲁胺降低capivasertib暴露的机制及对疗效的长期影响未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined inhibition of the androgen receptor (AR) and AKT may be beneficial in mCRPC with PTEN loss. PATIENTS AND METHODS: mCRPC patients who previously failed abiraterone and/or enzalutamide, received escalating doses of AZD5363 (capivasertib) starting at 320 mg twice daily (b.i.d.) given 4 days on and 3 days off, in combination with enzalutamide 160 mg daily. The co-primary endpoints were safety/tolerability and determining the maximum tolerated dose and recommended phase II dose; pharmacokinetics, antitumour activity, and exploratory biomarker analysis were also evaluated. RESULTS: Sixteen patients were enrolled, 15 received study treatment and 13 were assessable for dose-limiting toxicities (DLTs). Patients were treated at 320, 400, and 480 mg b.i.d. dose levels of capivasertib. The recommended phase II dose identified for capivasertib was 400 mg b.i.d. with 1/6 patients experiencing a DLT (maculopapular rash) at this level. The most common grade ≥3 adverse events were hyperglycemia (26.7%) and rash (20%). Concomitant administration of enzalutamide significantly decreased plasma exposure of capivasertib, though this did not appear to impact pharmacodynamics. Three patients met the criteria for response (defined as prostate-specific antigen decline ≥50%, circulating tumour cell conversion, and/or radiological response). Responses were seen in patients with PTEN loss or activating mutations in AKT, low or absent AR-V7 expression, as well as those with an increase in phosphorylated extracellular signal-regulated kinase (pERK) in post-exposure samples. CONCLUSIONS: The combination of capivasertib and enzalutamide is tolerable and has antitumour activity, with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway. CLINICAL TRIAL NUMBER: NCT02525068.
引用
- Kolinsky MP, Rescigno P, Bianchini D, et al. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2020. PMID: 32205016. doi:10.1016/j.annonc.2020.01.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。